Genocea Biosciences Inc. [NASDAQ: GNCA] closed the trading session at $2.45 on 09/22/20. The day’s price range saw the stock hit a low of $2.3873, while the highest price level was $2.6382.
The stocks have a year to date performance of 18.36 percent and weekly performance of -9.59 percent. The stock has been moved at 60.13 percent over the last six months. The stock has performed -2.78 percent around the most recent 30 days and changed 6.06 percent over the most recent 3-months.
If compared to the average trading volume of 1.11M shares, GNCA reached to a volume of 1980178 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Genocea Biosciences Inc. [GNCA]:
SVB Leerink have made an estimate for Genocea Biosciences Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 15, 2019. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on July 08, 2019, representing the official price target for Genocea Biosciences Inc. stock.
The Average True Range (ATR) for Genocea Biosciences Inc. is set at 0.24, with the Price to Sales ratio for GNCA stock in the period of the last 12 months amounting to 88.15. The Price to Book ratio for the last quarter was 9.80, with the Price to Cash per share for the same quarter was set at 0.68.
GNCA stock trade performance evaluation
Genocea Biosciences Inc. [GNCA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.59. With this latest performance, GNCA shares dropped by -2.78% in over the last four-week period, additionally plugging by 60.13% over the last 6 months – not to mention a drop of -29.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GNCA stock in for the last two-week period is set at 44.08, with the RSI for the last a single of trading hit 50.68, and the three-weeks RSI is set at 48.49 for Genocea Biosciences Inc. [GNCA]. The present Moving Average for the last 50 days of trading for this stock 2.77, while it was recorded at 2.48 for the last single week of trading, and 2.31 for the last 200 days.
Genocea Biosciences Inc. [GNCA]: An insightful look at the core fundamentals
Return on Total Capital for GNCA is now -116.18, given the latest momentum, and Return on Invested Capital for the company is -128.24. Return on Equity for this stock declined to -240.60, with Return on Assets sitting at -93.04. When it comes to the capital structure of this company, Genocea Biosciences Inc. [GNCA] has a Total Debt to Total Equity ratio set at 79.54. Additionally, GNCA Total Debt to Total Capital is recorded at 44.30, with Total Debt to Total Assets ending up at 37.86. Long-Term Debt to Equity for the company is recorded at 77.24, with the Long-Term Debt to Total Capital now at 41.82.
Reflecting on the efficiency of the workforce at the company, Genocea Biosciences Inc. [GNCA] managed to generate an average of -$660,169 per employee.Genocea Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
Earnings per share (EPS) analysis for Genocea Biosciences Inc. [GNCA] stock
With the latest financial reports released by the company, Genocea Biosciences Inc. posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.46/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 39.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GNCA.
Genocea Biosciences Inc. [GNCA]: Insider Ownership positions
There are presently around $33 million, or 46.60% of GNCA stock, in the hands of institutional investors. The top three institutional holders of GNCA stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 7,225,676, which is approximately 0% of the company’s market cap and around 0.20% of the total institutional ownership; BVF INC/IL, holding 2,018,398 shares of the stock with an approximate value of $4.95 million in GNCA stocks shares; and VANGUARD GROUP INC, currently with $1.92 million in GNCA stock with ownership of nearly 1.626% of the company’s market capitalization.
Positions in Genocea Biosciences Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 18 institutional holders increased their position in Genocea Biosciences Inc. [NASDAQ:GNCA] by around 390,067 shares. Additionally, 12 investors decreased positions by around 730,747 shares, while 9 investors held positions by with 12,433,422 shares. The mentioned changes placed institutional holdings at 13,554,236 shares, according to the latest SEC report filing. GNCA stock had 5 new institutional investments in for a total of 58,852 shares, while 3 institutional investors sold positions of 14,379 shares during the same period.